Arginine Deiminase: A Potential Inhibitor of Angiogenesis and Tumor Growth
Author Information
Author(s): Park I-S, Kang S-W, Shin Y-J, Chae K-Y, Park M-O, Kim M-Y, Wheatley D N, Min B-H
Primary Institution: Korea University
Hypothesis
Does recombinant arginine deiminase inhibit in vivo angiogenesis and affect tumor cell growth in the presence or absence of nitric oxide?
Conclusion
Recombinant arginine deiminase significantly inhibits angiogenesis and tumor growth by depleting arginine, a vital nutrient for cancer cells.
Supporting Evidence
- ADI treatment significantly inhibited capillary-like tube formation of HUVECs in a dose-dependent manner.
- At 0.046 U/ml, ADI produced an avascular zone beneath the disk in 88% of the treated chick embryos.
- Matrigel plugs treated with ADI remained pale, indicating no blood vessel formation after 5 days.
Takeaway
This study shows that a special enzyme can stop cancer cells from growing by taking away an important food they need, which also helps stop new blood vessels from forming.
Methodology
The study used in vitro and in vivo assays to evaluate the effects of recombinant arginine deiminase on endothelial cell tube formation and tumor growth.
Potential Biases
Potential bias due to the use of specific experimental models and conditions that may not reflect clinical scenarios.
Limitations
The study primarily focused on specific cell lines and may not fully represent the effects in all cancer types.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website